Hybio Pharmaceutical Lt (300199.SZ) traded flat 0 % during a 24 hours period ending at 05:59 PM Central Europe on Monday 26th. One Hybio Pharmaceutical Lt stock can currently be bought for about CNY 24.48 on popular exchanges. Current supply of Hybio Pharmaceutical Lt stocks is 883.3 mn. Hybio Pharmaceutical Lt has a current market capitalization of CNY 22.8 bn and approximately CNY 1.5 bn worth of Hybio Pharmaceutical Lt was traded on exchanges in the last 24 hours. Since last month end, Hybio Pharmaceutical Lt has traded 10.73 % up. Simple moving average of last 200 days is at CNY 23.27. The highest price of past 52 weeks was recorded at CNY 27.7 on 10/21/2026. 52 weeks low was at CNY 16.23 on 03/04/2026.
Summary of the latest news for Hybio Pharmaceutical Lt
The United Kingdom announced the creation of a national AI‑driven biological safety laboratory, a move that signals growing confidence in AI’s role across drug discovery and clinical practice. The initiative, supported by major AI firms and funded by government and private partners, aims to use machine learning to detect and monitor biological threats. In China, a new policy framework encourages the development of AI models for healthcare, with the health ministry outlining targets for AI‑enabled clinical applications by 2030. The same year, the medical‑service pricing system now lists AI‑assisted diagnosis as a reimbursable item, underscoring the sector’s shift toward integrated digital solutions. Companies actively applying AI in pharmaceuticals are reporting stronger commercial traction. Several firms have seen significant increases in revenue and orders as they leverage AI to accelerate protein engineering, virtual screening, and early‑stage drug design. Overall, the trend shows a consolidation of AI capabilities in the pharmaceutical supply chain, with expectations that AI will drive faster development cycles and broaden the range of investigational candidates entering clinical phases.
Here is how related stocks have performed in the past 24 hours:
Ninebot (689009.SS) traded flat 0 % and now trades at CNY 36.2. Current market capitalisation for Ninebot is CNY 27.1 bn. Ninebot has a current price to earnings ratio of 20.72. Ninebot Limited is set to release its latest quarterly financial results on 27 October 2026, covering the period ended 30 September 2026. Analysts anticipate a modest rise in earnings per share compared to the previous year, while revenue is expected to increase noticeably relative to the prior quarter. For the current fiscal year, consensus forecasts suggest a higher profit per share and a significant uptick in total revenue compared with last year’s figures. The company’s performance is therefore viewed as improving, with analysts noting stronger sales growth and a positive trend in profitability.
Changsha Jingjia Microelec (300474.SZ) traded flat 0 % and now trades at CNY 51.93. Changsha Jingjia Microelec has a market capitalisation of CNY 27.2 bn. Changsha Jingjia Microelectronics has reported a shift in its focus toward the integration of artificial intelligence and advanced manufacturing technologies within the broader “2+4+N” industrial framework promoted in the Changsha New Area. The company is participating in collaborative efforts with regional partners to develop embodied intelligent robots, leveraging its core components and training infrastructure. These initiatives aim to enhance the region’s capability to fuse AI, high‑end equipment, and smart logistics into a cohesive production ecosystem. While specific financial figures are not disclosed, the emphasis remains on expanding the company’s technological portfolio and strengthening its role in the evolving industrial landscape of Changsha.
Xingyun (300209.SZ) traded flat 0 % and now trades at CNY 28. Xingyun has a market capitalisation of CNY 27 bn. XINGYUN TECHNOLOGY CO LTD has reported a substantial increase in its announced computational and storage orders, reaching approximately 18.3 billion yuan this year. The company noted that key clients across several tiers—V, VB, and VC—have negotiated significant rent adjustments, with the VB client alone seeing a rise of over 230 percent in contractual value. XINGYUN attributes these gains to tightening market supply, accelerating client demand, and its own strong delivery capabilities. The combination of higher pricing, concentrated cluster deployments, and successful multi‑project completions is driving the company toward a stage of scalable profitability.
Jiangsu Yuyue Medical Equ (002223.SZ) traded flat 0 % and now trades at CNY 28.52. Current market capitalisation for Jiangsu Yuyue Medical Equ is CNY 26.9 bn. Current price/earnings ratio for Jiangsu Yuyue Medical Equ is 24.36. Jiangsu Yuyue Medical Equipment Co. reported that its third‑quarter performance showed an upward trend compared with the first half of the year. Domestic online sales continued to grow while adjustments to offline operations were largely complete. The company emphasized that its product pipeline remains robust, with new items being introduced across several lines, reinforcing its position in the domestic home medical device market. Overseas sales have also expanded, with export revenue contributing a growing share of total income. Particular attention was given to the company’s continuous growth in continuous glucose monitoring (CGM) services, driven mainly by the domestic market, and its leading market share there. Recent regulatory approvals in the European Union for its Anytime product series have paved the way for expanding international sales, and the firm plans to further develop subsequent product tiers and pursue additional registrations to broaden both domestic and global market presence.
Centre Testing (300012.SZ) traded flat 0 % and now trades at CNY 16.2. Centre Testing has a market capitalisation of CNY 26.9 bn. Centre Testing has a current price to earnings ratio of 23.03. Foreign investors hold more than 24 % of the shares in China’s CENTRE TESTING INTL GROUP, according to data released by the Shenzhen and Shanghai stock exchanges on 23 October. The company’s shares are owned by a mix of institutional investors, including QFII/RQFII programmes and global custodians. The information, sourced from a reputable financial news outlet, confirms that CENTRE TESTING INTL GROUP remains a significant investment for overseas stakeholders. No further details about the company’s financial performance or operational developments are included in the report.
About Hybio Pharmaceutical Lt
Hybio Pharmaceutical Co., Ltd., a peptide pharmaceutical company, specializes in conducting research, development, and manufacturing of polypeptide drugs both nationally and internationally within the health care sector, with a focus on the production of finished dosage products in relation to digestive system agents, immune modulators, PTH and Ca metabolic modulators, hormone and endocrine modulators, FD for circulatory and blood systems, antiviral agents, and hemostatic products. Additionally, the company offers peptide CRO and CMO services, as well as API products. Hybio Pharmaceutical Co., Ltd. was established in 1998 and has its main office in Shenzhen, People’s Republic of China. The official company website is accessible under www.hybio.com.cn , and the stock of this pharmaceutical company is traded on the Shenzhen Stock Exchange. The initial public offering (IPO) took place on April 7th, 2011.
